We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
+53.09%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$183M
AUM Growth
+$58.8M
Cap. Flow
-$4.5M
Cap. Flow %
-2.46%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$18.9M
2
PHVS icon
Pharvaris
PHVS
+$8.16M

Top Sells

Rank Stock Value
1
MAZE
Maze Therapeutics
MAZE
+$26.8M
2
KURA icon
Kura Oncology
KURA
+$4.71M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.28B
$119M 65.29%
4,778,581
+368,000
+8% +$8.16M
CYTK icon
2
Cytokinetics
CYTK
$10.6B
$25.2M 13.79%
+458,295
New +$18.9M
MAZE
3
Maze Therapeutics
MAZE
$1.51B
$13.6M 7.42%
522,657
-1,589,262
-75% -$26.8M
LYEL icon
4
Lyell Immunopharma
LYEL
$318M
$13M 7.12%
800,399
– –
XENE icon
5
Xenon Pharmaceuticals
XENE
$6.1B
$6.42M 3.52%
160,000
– –
RLAY icon
6
Relay Therapeutics
RLAY
$4B
$5.22M 2.86%
1,000,000
– –
KURA icon
7
Kura Oncology
KURA
$793M
– –
-816,882
Closed -$4.71M

Similar funds

BCM
Birmingham Capital Management Birmingham, Alabama $237M AUM 32.7% 1-Year Est. Return
ICMM
Integrated Capital Management (Michigan) Bloomfield, Michigan $237M AUM 23.03% 1-Year Est. Return
AG
ASO Group Road Town $237M AUM
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
EA
Evolution Advisers Richmond, Virginia $237M AUM 12.93% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return
TCM
Tekne Capital Management New York $237M AUM 62.98% 1-Year Est. Return

Foresite Capital Management IV's Q3 2025 Portfolio in Review

As of Q3 2025, Foresite Capital Management IV held 7 positions worth $183M, up 48% from $124M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management IV's Q3 2025 filing shows 1 new, 1 increased, 1 reduced and 1 closed positions. Its largest new stake was Cytokinetics: 458,295 shares worth $25.2M. The largest sale was Maze Therapeutics, an estimated $26.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management IV's largest Q3 2025 buy was Cytokinetics: 458,295 shares worth $25.2M.
  • Foresite Capital Management IV added most to Pharvaris in Q3 2025, an estimated $8.16M increase.
  • Foresite Capital Management IV's biggest Q3 2025 reduction was Maze Therapeutics, cutting an estimated $26.8M.
  • Foresite Capital Management IV fully exited Kura Oncology in Q3 2025, selling an estimated $4.71M.
  • Foresite Capital Management IV's ten largest holdings make up 100% of its $183M portfolio in Q3 2025.
  • Foresite Capital Management IV opened 1 new position and closed 1 in Q3 2025.
  • Foresite Capital Management IV's portfolio value rose 48% quarter-over-quarter to $183M.

Based on Foresite Capital Management IV's 13F filing for Q3 2025, filed 14 Nov 2025.